Novai: Funding, Investors & Team (Sep 2026)

Novai is a British biotechnology start-up, commercialising DARC Technology, an exploratory retinal biomarker for use in Age-related Macular Degeneration (AMD) & glaucoma clinical studies. DARC combines an innovative patented biologic with a state-of-the-art AI algorithm and uses standard imaging equipment to identify cellular level disease activity. DARC Technology can be used to measure the impact of current and future therapeutics and interventions by assessment of disease activity whilst identifying non-responders to existing and new interventions, resulting in the avoidance of costly, ineffective or un-required medical management. DARC helps to stratify patients in clinical trials, resulting in the creation of enriched patient cohorts, consisting of those at highest risk of rapid disease progression. DARC has been developed by Professor M Francesca Cordeiro at University College London through Wellcome Trust funding and is now approved as an exploratory biomarker by the FDA & MHRA. Following further analysis of Phase II data, several other indications may follow, including Multiple Sclerosis, Alzheimer’s Disease, Parkinson’s Disease, Diabetes Mellitus and Cancer.

Novai has raised $2.7M across 1 round on record. The most recent is a Seed of $2.7M announced in Oct 2021.

Novai's most recent funding round on record is a Seed of $2.7M, announced in Oct 2021.

Aman Khan is listed as CEO at Novai.

Novai is based in Reading, United Kingdom.

Novai is in the 11-50 employee band.

Novai's latest round of $2.7M is below the $5.5M median round size for Artificial Intelligence companies on FundedIQ across 7,233 tracked companies over the last two years.